Orphan drugs: A problem of public health and an economic stake;LES MEDICAMENTS ORPHELINS: PROBLEME DE SANTE PUBLIQUE ET ENJEUX ECONOMIQUES

Therapie

Volumn 51, Issue 6, 1996, Pages 647-653

  Brandissou, S ^a   Yagoubi, N ^b   Hasselot, N ^a  

^a LAVERAN MILITARY TEACHING HOSPITAL   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

Author keywords

Legislation; Orphan drug; Rare disease; Tropical disease

Indexed keywords

ALPHA2A INTERFERON; BOTULINUM TOXIN; CAFFEINE; CLOFAZIMINE; DIGOXIN ANTIBODY; ERYTHROPOIETIN; MEFLOQUINE; MODAFINIL; ORPHAN DRUG; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID;

DRUG INDUSTRY; ECONOMICS; EUROPE; FRANCE; LAW; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; UNITED STATES; DRUG LEGISLATION; DRUG MANUFACTURE; HUMAN; LEGAL ASPECT;

FRANCE; HUMANS; LEGISLATION, DRUG; ORPHAN DRUG PRODUCTION; PUBLIC HEALTH;

EID: 0030276363     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Stucki JC. The development of orphan drugs. A pharmaceutical company perspective. Prog Clin Biol Res 1985; 197: 95-104.
2. Health promotion and disease prevention amendments of 1984. Public Law 98-551.
3. Finkel MJ. The U.S. orphan drug development program: incentives and results. In: Scheinberg IH, Walshe J.M., eds. Orphan diseases and orphan drugs. Manchester: University Press, 1986: 159-168.
4. Daina E. Rare diseases and orphan drugs. Lancet 1994; 343: 1560-1561.
5. Wolf A. Les orphelins de la santé. INSERM Edition, Septembre 1994.
6. Van Woert MH. Orphan drug act. Prog Clin Biol Res 1985; 197: 7-9.
7. Orphan Drug Act. Public Law 97-414, 1983.
8. Asbury CH. The Orphan Drug Act. The first seven years. JAMA 1991; 265: 893-897.
9. Haffner ME. Orphan products. Ten years later and then some. Food Drug Law J 1994; 49: 593-601.
10. Finkel MJ. 'Orphan products'. Ind Sante 1985; 103: 41.
11. Scharf SF. Orphan drugs: The question of products liability. Am J Law Med 1985; 10: 491-513.
12. Weintraub M, Northington FK. Drugs that wouldn't die. JAMA 1986; 255: 2327-2328.
13. Affner ME. Unique aspects of orphan drug safety. Drug Inf J 1994; 28: 489-494.
14. Thoene JG. Current status of orphan disease drug development. Curr Opin Pediatr 1994; 6: 209-212.
15. Sanders CA. The Orphan Drug Act. Should it be changed? Arch Int Med 1993; 153: 2623-2625.
16. Seachrist L. Senators seek reform of Orphan Drug Act. J Natl Cancer Inst 1993; 85: 1984-1985.
17. Akimoto T. Partial revision of the Pharmaceutical Affairs Law. JPMA Update no 4: 3-6; June 4, 1993.
18. Loi du 8 décembre 1992, modifiant le livre V du code de la santé publique et relative à la pharmacie et au médicament (J.O. du 12/12/1992).
19. Décrêt no 94-568 du 8 Juillet 1994, relatif aux autorisations temporaires d'utilisation de certains médicaments à usage humain et modifiant le code de la sante publique. (J.O. du 10/07/1994).
20. Chevalier A. Les médicaments compassionnels, orphelins et importés. In: La Loi, le médicament, le Pharmacien Hospitalier. Onzième journée APHM 1994: 25-28.
21. Directive 91/507/CEE du conseil du 19 Juillet 1991 (J.O.C.E. L-214 du 26 Septembre 1991).
22. Anonyme. Médicaments orphelins. Bientôt une politique européenne. D & P Actualités 1996; 7: 7-10.
23. Tutin C. Bientôt un statut pour les orphelins? Abstract Hôpital 1995; 52: 8-10.
24. Van Woert MH. Current activities and future goals of orphan disease agences. Prog Clin Biol Res 1985; 197: 3-6.
25. Miller D. Biotechnology receives special attention in budget. PMA Newslett 1990; 32: 3.
26. Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-1470.
27. Garber AM. No price too high? N Engl J Med 1992; 327: 1676-1678.
28. Garber AM, Clarke AE, Goldman DP, Gluck ME. Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease. Office of Technology Assessment, U.S. Congress. Washington, DC: Government Printing Office, 1992.
29. Collier J. Dornase-alpha and orphan drugs. Lancet 1995; 346: 633.
30. Lewin R. Big first scored with nerve diseases. Science 1989; 345: 467.
31. Anonymous. Buying into the orphan drug market. Lancet 1995; 346 (8980): 917.
32. MacArthur D. Orphan drugs: Public service ... and private profit? PJB Publications, December 1987.
33. Hanesse B, Trechot Ph, Netter P, Royer RJ. Les médicaments orphelins: Le modèle américain. Rev Med Interne 1992; 13: 93-96.
34. Frasier D. Human growth hormone is not an orphan. N Engl J Med 1989; 321: 1124.
35. Amgen, Inc. v Chugai Pharmaceutical Company and Genetics Institute, 1989, WL 169006 (D Mass) and 13 USPQ 2, 1737.
36. Hearings before the House Subcommittee on Health and the Environment, 101st Cong., 2nd Sess. (February 7, 1990) (Testimony of Thomas Wiggans).
37. Harby K. Are orphan products program funds underused by nuclear medicine reseachers? J Nucl Med 1988; 29: 1011-1012.
38. Gershon D. Drugs bill to rein in profits. Nature 1994; 368: 381.
39. Peabody JW. Ruby A, Cannon P. The economics of orphan drug policy in the US: can the legislation be improved? Pharmacoeconomics 1995; 8: 374-384.
40. Levitt JA, Kelsey JV. The orphan drug regulation and related issues. Food Drug Law J 1993; 48: 525-532.